• linkedin
  • Increase Font
  • Sharebar

    A promising target for immunotherapy?

     
    • Downregulated miRNA clusters were characterized in bladder biopsy tissue obtained from patients with bladder outlet obstruction and could provide insights into the mechanism for loss of function.
    • MicroRNA-132 induced bladder hypertrophy and overactivity in a rodent model. Its effects on muscle contractility were consistent with its ability to downregulate acetylcholinesterase and upregulate molecules associated with overactivity.
    • Estrogen receptor gene networks may provide novel biomarkers for studying BPH and associated lower urinary tract symptoms.
    • Periprostatic fat in obese patients may contribute to prostate tissue remodeling.
    • Extracellular vesicles derived from amniotic fluid stem cells attenuated elevated VEGF signaling in a mouse model of Alport syndrome and the pathologic sequelae of the disease.
    • Patients with calcium stones and Randall’s plaque excrete distinct populations of miRNAs within urinary extracellular vesicles. These miRNAs contribute to stone pathogenesis and may serve as valuable biomarkers.
    • A biofabricated bone marrow-derived cell patch restored structure and function to radiation-injured bladders in a rat model.
    • Optogenetics offers a strategy to evoke control of discrete populations of bladder sensory fibers that could lead to better understanding of their role in bladder function and disease.

    More from Urology Times:

    Prostate Ca immunotherapy induces T-cell response

    Burnout, biopsy, BPH, and more: Post-AUA review

    Immunotherapy treats Ca based on genetic feature


    Subscribe to Urology Times to get monthly news from the leading news source for urologists.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results